Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Ocugen, Inc. (NasdaqCM: OCGN).
On June 10, 2021, the Company disclosed that it would pursue a “biologics license application” with the U.S. Food and Drug Administration for its COVID-19 vaccine candidate/product rather than the Emergency Use Authorization process that it had previously stated it would utilize.
The Company has been sued in a securities class action lawsuit for failing to disclose material information, violating federal securities laws, which is ongoing.
KSF’s investigation is focusing on whether Ocugen’s officers and/or directors breached their fiduciary duties to Ocugen’s shareholders or otherwise violated state or federal laws.
If you have information that would assist KSF in its investigation, or have been a long-term holder of Ocugen shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-ocgn/ to learn more.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.
To learn more about KSF, you may visit www.ksfcounsel.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210910005567/en/
Contacts
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
